01 Shift from Single-Use to Reusable and Sustainable Injection Pen Designs With increasing environmental awareness and stricter sustainability regulations, manufacturers are transitioning from traditional single-use disposable injection pens toward reusable and circular economy-based designs. As per the 2024 annual report of Novo Nordisk, the company launched the ReMed take-back scheme across several markets to collect and recycle used injection pens, and committed to developing reusable devices while reducing the plastic footprint per patient by 2026.This transition reflected the industry’s move toward eco-friendly innovation, focusing on materials reuse, reduced medical waste, and carbon-neutral production processes. Such advancements not only addressed environmental and regulatory demands but also improved long-term affordability and alignment with global healthcare systems' sustainability goals.
02 Shift Towards Smart and Connected Injection Pens with Digital Dose Tracking With the growing emphasis on treatment accuracy and patient adherence, the injection pen market is witnessing a major transition from standard mechanical pens to smart, connected devices integrated with digital dose tracking capabilities. Manufacturers introduced Bluetooth-enabled injection pens that synchronize with mobile health applications to record dosage history as well as monitor administration patterns. Such evolution reflected the shift of industry towards data-driven and patient-centric drug delivery systems, which have enhanced treatment adherence, real-time monitoring and remote healthcare support, which further allowed patients and healthcare providers to manage the chronic conditions more efficiently.
01 Integration of Temperature Controlled Storage in Pens for Biologics The growing demand to maintain the stability and potency of temperature-sensitive biologics has contributed to the growth of the injection pen market. Otsuka Pharmaceutical highlighted in its press release the development of injection pens with built-in temperature control systems for peptide therapies, which further ensured drug integrity during storage and transport. Such factors underscored the increasing demand for advanced injection pens that enhanced patient safety, convenience, and efficient self-administration of biologics.
01 Needle Stick Injury Risks in Injection Pens The risk of accidental needle stick injuries remains a barrier to the widespread adoption of injection pens, despite advancements in safety features. According to the safety reports from the U.S. Centers for Disease Control and Prevention (CDC), accidental needle stick incidents continued to occur, particularly in regions with limited access to safe disposal methods. Such concerns underscored the ongoing demand for enhanced safety mechanisms and proper disposal solutions to ensure safe use of injection pens, especially in home and low-resource healthcare settings.
01 Expansion of Biologics and Specialty Drug Delivery via Injection Pens The rising prevalence of chronic diseases and the growing use of biologics have created an opportunity for injection pens as patient-friendly delivery systems. Manufacturers are increasingly developing pens for therapies such as monoclonal antibodies, GLP-1 receptor agonists, and other biologics that require precise dosing at home. For example, in June 2025, Eli Lilly highlighted in its press release the launch of its new prefilled pen for a GLP-1 therapy, designed to simplify administration for patients with diabetes and obesity, while ensuring stability and dose accuracy. This trend underscored the potential for injection pens to expand access to complex therapies and improve treatment adherence.
March 2026 Novo Nordisk expanded its injection pen portfolio with continued advancements in reusable and prefilled pen delivery systems, supporting diabetes and obesity care through improved patient convenience and medication adherence.
January 2026 Eli Lilly expanded its injectable drug delivery ecosystem with next-generation pen-based delivery solutions designed to support incretin-based therapies and improve patient experience in chronic disease management.
October 2025 Ypsomed expanded its self-injection device portfolio with new autoinjector and injection pen technologies, strengthening partnerships with pharmaceutical companies for diabetes, obesity, and biologic drug delivery applications.
August 2025 Sanofi expanded its insulin delivery solutions portfolio with improved injection pen technologies designed to enhance ease of use, dosing accuracy, and patient support for diabetes management.